Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03430843 · ClinicalTrials.gov registry record · Phase 3

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene.

Completed
Registry status
Phase 3
Development phase
512
Enrollment target
20
Study locations

NCT03430843 is a Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC) that has completed, run by BeiGene. The registered enrollment target is 512 participants, roughly in line with the 517-participant average among 5 other Esophageal Squamous Cell Carcinoma (ESCC) trials with a reported enrollment target. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03430843, a Phase 3 study of Esophageal Squamous Cell Carcinoma (ESCC), has completed, sponsored by BeiGene.

COMPLETED
Registry status
Phase 3
Development phase
512 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.

Conditions Studied

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

  • DRUG Docetaxel
  • DRUG Tislelizumab
  • DRUG Paclitaxel
  • DRUG Irinotecan

Study Locations (20)

Other

  • Imelda Ziekenhuis Bonheiden - Bonheiden
  • Cliniques Universitaires Saint Luc - Brussels
  • Uz Antwerpen - Edegem
  • University Hospitals Leuven - Leuven

Fujian

  • Fujian Medical University Union Hospital - Fuzhou
  • The First Affiliated Hospital of Fujian Medical University - Fuzhou
  • Fujian Cancer Hospital - Fuzhou
  • The First Affiliated Hospital of Xiamen University - Xiamen

Guangdong

  • The First Affiliated Hospital, Sun Yat Sen University - Guangzhou
  • The Sixth Affiliated Hospital, Sun Yat Sen University - Guangzhou
  • Cancer Hospital of Shantou University Medical College - Shantou
  • Peking University Shenzhen Hospital - Shenzhen

Beijing Municipality

  • Beijing Friendship Hospital, Capital Medical University - Beijing
  • Beijing Cancer Hospital - Beijing
  • Peking Union Medical College Hospital - Beijing

Michigan

  • Henry Ford Hospital - Detroit

Ohio

  • Toledo Clinic Cancer Center - Toledo

Anhui

  • The Second Hospital of Anhui Medical University - Hefei

Hebei

  • Affiliated Hospital of Hebei University - Baoding

Trial Details

FieldValue
Enrollment Target 512 participants
Start Date 2018-01-26
Est. Completion 2022-12-28
Phase Phase 3

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03430843

The ClinicalTrials.gov registry entry for NCT03430843 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 517-participant average among 5 other Esophageal Squamous Cell Carcinoma (ESCC) trials with a reported enrollment target. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Esophageal Squamous Cell Carcinoma (ESCC) appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.

NCT03430843 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Fujian, Guangdong.

Frequently Asked Questions

What is clinical trial NCT03430843 about?

NCT03430843 is a clinical study titled "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma". The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.

What is the current status of trial NCT03430843?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2018-01-26. Estimated completion is 2022-12-28.

What conditions does trial NCT03430843 study?

This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma (ESCC).

What interventions are being tested in trial NCT03430843?

The interventions under investigation include: Docetaxel (DRUG), Tislelizumab (DRUG), Paclitaxel (DRUG), Irinotecan (DRUG).

Who is sponsoring clinical trial NCT03430843?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03430843 being conducted?

This trial has 20 study locations across Michigan, Ohio, Anhui, Beijing Municipality, Fujian. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Esophageal Squamous Cell Carcinoma (ESCC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Esophageal Squamous Cell Carcinoma (ESCC)

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.